ClinicalTrials.gg
CompletedNCT02641379Updated Aug 4, 2016Results posted

A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)

A Phase 4 interventional study of Peginterferon alfa-2a and Ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 21 sites in Austria. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-08-04.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
737
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
8th of 83
737 · median 129
Started
2003
with 11 others
Phase 4
48 of 83
none open now
Registered
77th of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 8th largest by enrollment, is one of 12 that started in 2003, is one of 48 in phase 4, and was the 77th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This study will compare the efficacy and safety of 2 different treatment durations of peginterferon alfa-2a (Pegasys) plus ribavirin in patients with CHC. The anticipated time on study treatment is 1-2 years, and the target sample size is greater than (>) 500 individuals.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients with chronic and genotype 1 (1a or 1b) or genotype 4
  • Age between 18 and 70 years
  • Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test
  • Present with at least one elevated serum alanine-aminotransferase () level higher than normal in the last 6 months before therapy start including the screening period
  • Positive HCV-RNA level in serum
  • Laboratory parameters (within 35 days prior to study start): -Hepatitis A anti - IgM negativity, -Ab negativity, negativity, values > 12 g/dl in women or > 13 g/dl in men, Leukocyte count (WBC) > 3 000 /mcl, count > 100 000/mcl, Creatinine not 1.5 times higher than normal, normal TSH, normal uric acid with a maximum tolerance of 15 % in patients without history of gout
  • Liver findings within 6 months prior to study therapy consistent with the diagnosis of chronic hepatitis C infection with or without compensated cirrhosis. Biopsies older than 1 year are eligible only after direct communication with the principal investigator
  • Negative urine or blood pregnancy test (for women of ) documented within the 24-hour period prior to the first dose of study drug. If there is no laboratory report existing, the physician should make an entry in the medical history that the pregnancy test was negative.
  • All fertile females receiving ribavirin must be using two forms of effective during treatment and during the 6 months after treatment end. All fertile men with female partners must be using two forms of effective contraception during treatment and during the 7 months after treatment end.
  • Written obtained

Exclusion criteria

Exclusion Criteria:

  • Any IFN and / or Pegylated IFN and ribavirin therapy at any previous time
  • Class B or C cirrhosis as coded by classification
  • Women with ongoing pregnancy or breast feeding
  • Therapy with any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of and radiation) 6 months prior to the first dose of study drug
  • Any drug 6 weeks prior to the first dose of study drug
  • Drug addiction within 1 year prior to study start (patients participating in an official methadone program are eligible)
  • Diabetes mellitus in patients receiving an insulin therapy
  • Hemophiliac patients (due to the increased risk of requested liver )
  • History or other evidence of a medical condition associated with chronic liver disease other than (e.g., hemochromatosis, hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures)
  • History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
  • History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease. Exception: if there is a current psychiatric report which certifies there is no to interferon therapy, patient may be included
  • History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis etc.)
  • History or other evidence of chronic pulmonary disease associated with functional limitation
  • History of a severe seizure disorder or current anticonvulsant use
  • History of severe cardiac disease and severe coronary heart disease within the last 6 months (angina pectoris, congestive heart failure, recent myocardial infarction, severe hypertension or significant arrhythmia). If there is clinical suspicion of coronary heart disease cardiologic workup of the patient prior to study entry is recommended.
  • History of thyroid disease poorly controlled on prescribed medications, elevated thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease
  • History or other evidence of severe illness, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
  • History of major organ transplantation with an existing functional graft
  • Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration)
  • Inability or unwillingness to provide or abide by the requirements of the study

Additional exclusion criteria concerning ribavirin:

  • Male partners of women who are pregnant
  • Any patient with an increased baseline risk for anemia (e.g. thalassemia, spherocytosis, history of GI bleeding, etc) or for whom anemia would be medically problematic
  • Patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled if, in the judgment of the investigator, an acute decrease in by up to 4 g/dL would not be well-tolerated
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
737 participants (actual)

Study arms

  • Experimental
    PEG-IFN 24 weeks

    Participants will receive PEG-IFN (180 microgram \[mcg\]), subcutaneously (sc), once weekly for 24 weeks and Ribavirin 1000-1200 milligram per day (mg/day) (\<75 kilogram (kg); \>75 kg) for 24 weeks.

    Drug: Peginterferon alfa-2a · Drug: Ribavirin

  • Experimental
    PEG-IFN 24/72 weeks

    Participants will receive PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (\<75kg; \>75 kg) till week 24; if patient is still HCV RNA positive. Treatment will be stopped if participant is HCV RNA negative at week 24 -treatment with PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (\<75kg; \>75 kg) till week 72

    Drug: Peginterferon alfa-2a · Drug: Ribavirin

  • Experimental
    PEG-IFN 48 weeks

    Participants will receive PEG-IFN (180 mcg), sc, once weekly for 48 weeks and Ribavirin 1000-1200 mg/day (\<75kg; \>75 kg) for 48 weeks.

    Drug: Peginterferon alfa-2a · Drug: Ribavirin

  • Experimental
    PEG-IFN 72 weeks

    Participants will receive PEG-IFN (180 mcg), sc, once weekly for 72 weeks and Ribavirin 1000-1200 mg/day (\<75 kg; \> 75 kg) for 72 weeks.

    Drug: Peginterferon alfa-2a · Drug: Ribavirin

Interventions

  • PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n

    Also known as: Pegasys

  • Ribavirin is available as 200 mg tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Relapse Rate in Groups A and B by Genotype at the End of Follow-up (Part 1)

    Relapse rate (RR) was defined as the percentage of participants with non-detectable HCV RNA (\< 100 copies/ml) at the end of treatment and detectable HCV RNA at the end of follow-up. End of treatment was defined as Week 48 for Group A and Week 72 for Group B, respectively. The end of follow-up was defined as Week 72 for Group A and Week 96 for Group B, respectively. Relapse rate for treatment Groups A and B, stratified for genotype (Genotype I and Genotype IV) and Week 4 response (\< 600 units/milliliter \[U/ml\] and \>= 600 U/ml) is presented.

    Time frame: Up to Week 96

  2. Percentage of Participants Achieving Sustained Virological Response in Groups A1, B1, and E by Genotype at the End of Follow-up (Part 2)

    The Sustained Virological Response (SVR) was defined as the percentage of participants in each group with non-detectable HCV RNA result at 24 weeks post completion of the treatment period (HCV RNA \< 15 IU/ml at Week 72 of Groups A1 and E, and at Week 96 of Group B1). Participants without a HCV RNA results at this time point were considered as non-responders. The end of follow-up was defined as Week 72 for Groups A1 and E, and Week 96 for Group B1. The SVR for treatment Groups A1 + B1 and E, stratified for genotype (Genotype I and Genotype IV) is presented.

    Time frame: Up to Week 96

Secondary outcomes

  1. Percentage of Participants With Virological Response Rate in Groups A, B, C, and D at the End of Treatment Period (Part 1)

    End of treatment response (ETR) rate was defined as the percentage of participants in each group with non-detectable HCV RNA at completion of the treatment period (HCV negative at Week 24 of Group D, Week 48 of Group A and at Week 72 of Groups B and C). Participants without a HCV RNA results at this time point were considered as non-responders. End of the treatment period was defined as Week 48 for Group A, Week 72 for Groups B and C, and Week 24 for Group D.

    Time frame: Up to Week 72

  2. Percentage of Participants Achieving Sustained Virological Response in Groups A, B, C, and D at the End of Follow-up (Part 1)

    The SVR was defined as the percentage of participants in each group with a non-detectable HCV RNA result at 24 weeks post-completion of the treatment period (HCV RNA \< 15 IU/ml at Week 48 of Group D, at Week 72 of Group A, and at Week 96 of Groups B and C). Participants without a HCV RNA PCR at this time point were considered as non-responders in this calculation. The end of follow-up was defined as Week 72 for Group A, Week 96 for Groups B and C, and Week 48 for Group D.

    Time frame: Up to Week 96

  3. Mean Short Form-36 Questionnaire Scores for Groups A and B Over Time (Part 1)

    The Short Form-36 (SF-36) is a quality of life instrument consisting of a 36-item questionnaire. The SF-36 items were scored and transformed according to the SF-36 Health Survey Manual and Interpretation Guide. Summary scores for SF-36 dimensions (physical functioning, role functioning, bodily pain, general health, vitality, social functioning, mental health, health transition) as well as physical and mental summary measures were compiled after imputation of mean scores for missing items if more than 50% of dimension-related items were available. Scores for health transition ranged from 0 (worst) to 5 (best). Scores for all other dimensions ranged from 0 (worst) to 100 (best). The mean SF-36 scores are presented at Baseline (Day 1), Week 24, Week 48, Week 72 (for Groups A and B) and at Week 96 (for Group B). Lower score indicate worsening.

    Time frame: Baseline (Day 1), Week 24, Week 48, Week 72, and Week 96

  4. Mean Fatigue Severity Scale Scores for Groups A and B Over Time (Part 1)

    The Fatigue Severity Scale (FSS) is an instrument consisting of 10 self-administered questions. The FSS items were scored by calculating the average response to all answered items (including the 9 questions and the fatigue symptoms). Each of the 9 questions had answers within a score range of 1-7. A score of 1 for any question indicates less fatigue in everyday life and a score of 7 indicates a higher likelihood of fatigue in everyday life. The mean FSS scores are presented at Baseline (Day 1), Week 24, Week 48 and Week 72 (for Groups A and B) and at Week 96 (for Group B).

    Time frame: Baseline (Day 1), Week 24, Week 48 and Week 72, and Week 96

  5. Number of Participants With Fibrosis Grades 0 to 4 at Baseline (Part 1)

    Liver fibrosis stage was scored using the METAVIR system (Grade 0 to 4). Grade 0 indicates no fibrosis, Grade 1 indicates stellate enlargement of portal tract but without septa formation, Grade 2 indicates enlargement of portal tract with rare septa formation, Grade 3 indicates numerous septa without cirrhosis and grade 4 indicates cirrhosis. The number of participants with fibrosis grades ranging from 0 to 4 at Baseline is presented.

    Time frame: Baseline (Day 1)

  6. Number of Participants With Adverse Events and Serious Adverse Events (Part 1)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.

    Time frame: Up to Week 96

  7. Percentage of Participants With Relapse Rates in Groups A1 and B1 at the End of Follow-up (Part 2)

    Virological relapse rate was defined as percentage of participants with non-detectable HCV RNA (\< 15 IU/ml) at the EoT and detectable HCV RNA (≥ 15 IU/ml) at the end of FU. The end of treatment was defined as Week 48 in Group A1 and Week 72 in Group B1 and the end of follow-up was defined as Week 72 in Group A1 and Week 96 in Group B1.

    Time frame: Up to Week 96

  8. Percentage of Participants With Virological Response Rates in Group A1, B1, C and D at the End of the Treatment Period (Part 2)

    ETR virological response rate at the end of treatment period was defined as the percentage of participants in each group with non-detectable HCV RNA at completion of the treatment period (HCV RNA quantitative PCR result \< 15 IU/ml at Week 24 for Group D, at Week 48 for Group A1, at Week 72 for Groups B1 and C). Participants without a HCV RNA PCR (missing values) at this time point were considered as non-responders in this calculation. The end of treatment period was defined as Week 48 for Group A1, Week 72 for Groups B1 and C1, and Week 24 for Group D.

    Time frame: Up to Week 72

  9. Percentage of Participants Achieving Sustained Virological Response in Groups C and D by Genotype at the End of Follow-up (Part 2)

    The SVR was defined as the percentage of participants in each group with non-detectable HCV RNA result at 24 weeks post completion of the treatment period (HCV RNA \< 15 IU/ml at Week 48 of Group D and at Week 96 of Group C). Participants without a HCV RNA results at this time point were considered as non-responders. The end of follow-up was defined as Week 96 for Group C and Week 48 for Group D.

    Time frame: Up to Week 96

  10. Mean Short Form-36 Questionnaire Scores for Groups A1, B1, and C Over Time (Part 2)

    The SF-36 is a quality of life instrument consisting of a 36-item questionnaire. The SF-36 items were scored and transformed according to the SF-36 Health Survey Manual \& Interpretation Guide. Summary scores for SF-36 dimensions (physical functioning, role functioning, bodily pain, general health, vitality, social functioning, mental health, health transition) as well as physical and mental summary measures were compiled after imputation of mean scores for missing items if more than 50% of dimension-related items were available. Scores for health transition ranged from 0 (worst) to 5 (best). Scores for all other dimensions ranged from 0 (worst) to 100 (best). The mean SF-36 scores were presented at Baseline (Day 1), Week 24, Week 48, Week 72 (for Groups A1, B1 and C) and at Week 96 (for Groups B1 and C). Lower score indicate worsening.

    Time frame: Baseline (Day 1), Week 24, Week 48, Week 72, and Week 96

  11. Mean Fatigue Severity Scale Scores for Groups A1, B1 and C Over Time (Part 2)

    The FSS is an instrument consisting of 10 self-administered questions. The FSS items were scored by calculating the average response to all answered items (including the 9 questions and the fatigue symptoms). Each of the 9 questions had answers within a score range of 1-7. A score of 1 for any question indicates less fatigue in everyday life and a score of 7 indicates a higher likelihood of fatigue in everyday life. The mean FSS scores are presented at Baseline (Day 1), Week 24, Week 48 and Week 72 (for Groups A1, B1 and C) and at Week 96 (for Groups B1 and C).

    Time frame: Baseline (Day 1), Week 24, Week 48 and Week 72, and Week 96

  12. Number of Participants With Fibrosis Grades 0 to 4 at Baseline (Part 2)

    Liver fibrosis stage was based upon biopsy and scored using the METAVIR system (Grade 0 to 4). Grade 0 indicates no fibrosis, Grade 1 indicates stellate enlargement of portal tract but without septa formation, Grade 2 indicates enlargement of portal tract with rare septa formation, Grade 3 indicates numerous septa without cirrhosis and grade 4 indicates cirrhosis. The number of participants with fibrosis grades ranging from 0 to 4 at Baseline (Day 1) is presented.

    Time frame: Baseline (Day 1)

  13. Number of Participants With Adverse Events and Serious Adverse Events (Part 2)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.

    Time frame: Up to Week 96

07

Results

Posted Aug 4, 2016

Participant flow

This study was conducted in 2 parts. Part 1 was conducted from 16 May 2003 to 12 September 2008 at 21 centers in Austria; Part 2 of this study was conducted from 19 October 2009 to 15 November 2013 at 15 centers in Austria.

Participant flow — Overall Study
MilestonePEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1)PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2)PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2)
Started142152781561736252042458
Completed107101713902012136360
Not completed3551711717161319698
Withdrew: Exclusion criterion during screening10012000000
Withdrew: Withdrawal of informed consent01000001000
Withdrew: Adverse event78225150115
Withdrew: Lack of efficacy00200205000
Withdrew: Participant unable to attend study visit410125111020
Withdrew: Participant's compliance01010200111
Withdrew: Participant cannot be reached44082101021
Withdrew: Pcr positive at week 2415216200638010
Withdrew: Pcr positive at follow up 210000000000
Withdrew: Participant showed relapse10000010000
Withdrew: Participant stopped study/treatment13100120100
Withdrew: Therapy stopped due to misunderstanding10000000000
Withdrew: Financial problems01000000000
Withdrew: Pcr positive at week 6801000000000
Withdrew: Pcr positive at week 4801000000000
Withdrew: Pcr not performed at week 1200100000000
Withdrew: No pcr at baseline00100000000
Withdrew: Pcr positive at week 2800100000000
Withdrew: Pcr sample for week 4 not drawn00010000000
Withdrew: Inclusion criteria not fulfilled00010000000
Withdrew: Baseline viral load unavailable00010000000
Withdrew: Blood could not be drawn00001000000
Withdrew: Protocol violation00002000100
Withdrew: Participation in sili rescue study00000100000
Withdrew: Lost to follow-up00000000100
Withdrew: Source data not found00000100000
Withdrew: Participant showed weight reduction00000001000
Withdrew: Non-response week 1200000001000
Withdrew: No 2 log drop at week 1200000000001
Withdrew: Negative pcr result00000000010
Withdrew: Participant's pcr high00000001000
Withdrew: Participant treated after week 2400000000100
Withdrew: Missing pcr result at week 800000000010
Withdrew: Pcr positive00000010000

Outcome measures

PrimaryPercentage of Participants With Relapse Rate in Groups A and B by Genotype at the End of Follow-up (Part 1)

Relapse rate (RR) was defined as the percentage of participants with non-detectable HCV RNA (\< 100 copies/ml) at the end of treatment and detectable HCV RNA at the end of follow-up. End of treatment was defined as Week 48 for Group A and Week 72 for Group B, respectively. The end of follow-up was defined as Week 72 for Group A and Week 96 for Group B, respectively. Relapse rate for treatment Groups A and B, stratified for genotype (Genotype I and Genotype IV) and Week 4 response (\< 600 units/milliliter \[U/ml\] and \>= 600 U/ml) is presented.

Time frame:
Up to Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Relapse Rate in Groups A and B by Genotype at the End of Follow-up (Part 1)
Percentage of participantsPEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)
Genotype I, Week 4 response < 600 U/ml,n= 130, 13622.0 (10.6 to 37.6)8.3 (1.8 to 22.5)
Genotype I,Week 4 response >=600 U/ml, n =130, 13652.7 (38.8 to 66.3)30.0 (17.9 to 44.6)
Genotype IV, Week 4 response < 600 U/ml, n =12, 160.0 (0.0 to 52.2)42.9 (9.9 to 81.6)
Genotype IV, Week 4 response >=600 U/ml, n =12, 1680.0 (28.4 to 99.5)80.0 (28.4 to 99.5)
Statistical analysis
  • PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) vs PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) · Chi-squared · p = 0.1002
  • PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) vs PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) · Chi-squared · p = 0.0184
  • PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) vs PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) · Chi-squared · p = 0.0910
  • PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) vs PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) · Chi-squared · p = 1.0000
PrimaryPercentage of Participants Achieving Sustained Virological Response in Groups A1, B1, and E by Genotype at the End of Follow-up (Part 2)

The Sustained Virological Response (SVR) was defined as the percentage of participants in each group with non-detectable HCV RNA result at 24 weeks post completion of the treatment period (HCV RNA \< 15 IU/ml at Week 72 of Groups A1 and E, and at Week 96 of Group B1). Participants without a HCV RNA results at this time point were considered as non-responders. The end of follow-up was defined as Week 72 for Groups A1 and E, and Week 96 for Group B1. The SVR for treatment Groups A1 + B1 and E, stratified for genotype (Genotype I and Genotype IV) is presented.

Time frame:
Up to Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Sustained Virological Response in Groups A1, B1, and E by Genotype at the End of Follow-up (Part 2)
Percentage of participantsPEG-IFN Alfa 2a + Ribavirin 48 Weeks (Group A1) (Part 2)PEG-IFN Alfa 2a + Ribavirin 72 Weeks (Group B1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2)
Genotype I, n = 33, 23, 3930.3 (15.6 to 48.7)34.8 (16.4 to 57.3)64.1 (47.2 to 78.8)
Genotype IV, n = 3, 2, 633.3 (0.8 to 90.6)0.0 (0.0 to 84.2)50.0 (11.8 to 88.2)
Statistical analysis
  • PEG-IFN Alfa 2a + Ribavirin 48 Weeks (Group A1) (Part 2) vs PEG-IFN Alfa 2a + Ribavirin 72 Weeks (Group B1) (Part 2) vs PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2) · Cochran-Mantel-Haenszel · p = 0.0021 (The SVR rate i.e., 32.1% participants with genotype I who achieved SVR with 95 % confidence interval of 20.3 to 46.0 in groups A1+B1 was compared with SVR rate in group E using Cochran-Mantel-Haenszel method .)
  • PEG-IFN Alfa 2a + Ribavirin 48 Weeks (Group A1) (Part 2) vs PEG-IFN Alfa 2a + Ribavirin 72 Weeks (Group B1) (Part 2) vs PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2) · Cochran-Mantel-Haenszel · p = 0.3031 (The SVR rate i.e., 20.0% participants with genotype IV who achieved SVR with 95 % confidence interval of 0.5 to 71.6 in groups A1+B1 was compared with SVR rate in group E using Cochran-Mantel-Haenszel method .)
SecondaryPercentage of Participants With Virological Response Rate in Groups A, B, C, and D at the End of Treatment Period (Part 1)

End of treatment response (ETR) rate was defined as the percentage of participants in each group with non-detectable HCV RNA at completion of the treatment period (HCV negative at Week 24 of Group D, Week 48 of Group A and at Week 72 of Groups B and C). Participants without a HCV RNA results at this time point were considered as non-responders. End of the treatment period was defined as Week 48 for Group A, Week 72 for Groups B and C, and Week 24 for Group D.

Time frame:
Up to Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants With Virological Response Rate in Groups A, B, C, and D at the End of Treatment Period (Part 1)
Percentage of participantsPEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1)
Percentage of Participants With Virological Response Rate in Groups A, B, C, and D at the End of Treatment Period (Part 1)74.6 (66.7 to 81.6)64.5 (56.3 to 72.1)9.0 (3.7 to 17.6)92.3 (86.9 to 96.0)
SecondaryPercentage of Participants Achieving Sustained Virological Response in Groups A, B, C, and D at the End of Follow-up (Part 1)

The SVR was defined as the percentage of participants in each group with a non-detectable HCV RNA result at 24 weeks post-completion of the treatment period (HCV RNA \< 15 IU/ml at Week 48 of Group D, at Week 72 of Group A, and at Week 96 of Groups B and C). Participants without a HCV RNA PCR at this time point were considered as non-responders in this calculation. The end of follow-up was defined as Week 72 for Group A, Week 96 for Groups B and C, and Week 48 for Group D.

Time frame:
Up to Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Sustained Virological Response in Groups A, B, C, and D at the End of Follow-up (Part 1)
Percentage of participantsPEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1)
Percentage of Participants Achieving Sustained Virological Response in Groups A, B, C, and D at the End of Follow-up (Part 1)45.1 (36.7 to 53.6)48.0 (39.9 to 56.3)6.4 (2.1 to 14.3)73.7 (66.1 to 80.4)
SecondaryMean Short Form-36 Questionnaire Scores for Groups A and B Over Time (Part 1)

The Short Form-36 (SF-36) is a quality of life instrument consisting of a 36-item questionnaire. The SF-36 items were scored and transformed according to the SF-36 Health Survey Manual and Interpretation Guide. Summary scores for SF-36 dimensions (physical functioning, role functioning, bodily pain, general health, vitality, social functioning, mental health, health transition) as well as physical and mental summary measures were compiled after imputation of mean scores for missing items if more than 50% of dimension-related items were available. Scores for health transition ranged from 0 (worst) to 5 (best). Scores for all other dimensions ranged from 0 (worst) to 100 (best). The mean SF-36 scores are presented at Baseline (Day 1), Week 24, Week 48, Week 72 (for Groups A and B) and at Week 96 (for Group B). Lower score indicate worsening.

Time frame:
Baseline (Day 1), Week 24, Week 48, Week 72, and Week 96
Reported as:
Mean · scores on a scale
Mean Short Form-36 Questionnaire Scores for Groups A and B Over Time (Part 1)
scores on a scalePEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)
Physical Functioning, Baseline, n = 106, 12186.9 ± 15.187.0 ± 17.8
Physical Functioning, Week 24, n = 77, 9061.8 ± 28.269.2 ± 22.6
Physical Functioning, Week 48, n = 67, 7766.1 ± 26.266.8 ± 23.1
Physical Functioning, Week 72, n = 65, 6889.8 ± 14.170.3 ± 24.6
Physical Functioning, Week 96, n = 0, 59NA ± NA87.0 ± 20.4
Role Functioning - Physical, Baseline,n = 105, 12074.7 ± 36.376.2 ± 36.9
Role Functioning - Physical, Week 24, n = 77, 8839.0 ± 43.045.7 ± 41.9
Role Functioning - Physical, Week 48, n = 66, 7640.7 ± 39.942.2 ± 44.0
Role Functioning - Physical, Week 72, n = 65, 6781.5 ± 32.947.4 ± 43.5
Role Functioning - Physical, Week 96, n = 0, 58NA ± NA84.5 ± 29.9
Bodily Pain, Baseline, n = 103, 12082.3 ± 22.583.5 ± 22.9
Bodily Pain, Week 24, n = 76, 9168.2 ± 31.170.0 ± 29.6
Bodily Pain, Week 48, n = 67, 7769.5 ± 28.666.8 ± 30.6
Bodily Pain, Week 72, n = 64, 7085.4 ± 23.267.3 ± 29.3
Bodily Pain, Week 96, n = 0, 61NA ± NA90.2 ± 19.8
General Health, Baseline, n = 102, 11964.5 ± 17.966.3 ± 19.7
General Health, Week 24, n = 75, 8358.9 ± 19.055.1 ± 22.8
General Health, Week 48, n = 63, 7458.1 ± 20.256.3 ± 19.2
General Health, Week 72, n = 65, 6271.7 ± 18.860.1 ± 19.3
General Health, Week 96, n = 0, 59NA ± NA70.3 ± 18.5
Vitality, Baseline, n = 103, 11656.8 ± 20.958.9 ± 22.5
Vitality, Week 24, n = 75, 8840.3 ± 24.040.6 ± 23.6
Vitality, Week 48, n = 66, 7740.6 ± 23.841.2 ± 21.2
Vitality, Week 72, n = 63, 6766.9 ± 18.943.5 ± 22.4
Vitality, Week 96, n = 0, 59NA ± NA62.9 ± 21.1
Social Functioning, Baseline, n = 105, 12179.8 ± 21.981.6 ± 22.0
Social Functioning, Week 24, n = 77, 9164.4 ± 28.564.1 ± 30.3
Social Functioning, Week 48, n = 67, 7871.6 ± 24.057.2 ± 27.5
Social Functioning, Week 72, n = 65, 7086.3 ± 22.363.8 ± 29.4
Social Functioning, Week 96, n = 0, 61NA ± NA83.4 ± 23.4
Role Functioning - Emotional,Baseline,n = 104, 12071.5 ± 39.375.8 ± 36.6
Role Functioning - Emotional, Week 24, n = 76, 8836.8 ± 42.443.9 ± 43.3
Role Functioning - Emotional, Week 48, n = 66, 7441.7 ± 41.042.8 ± 42.9
Role Functioning - Emotional, Week 72, n = 65, 6680.5 ± 32.843.4 ± 43.4
Role Functioning - Emotional, Week 96, n = 0, 58NA ± NA84.5 ± 31.4
Mental Health, Baseline, n = 103, 11569.6 ± 18.771.9 ± 19.1
Mental Health, Week 24, n = 76, 8860.7 ± 19.357.9 ± 21.5
Mental Health, Week 48, n = 66, 7762.6 ± 19.859.6 ± 20.7
Mental Health, Week 72, n = 63, 6776.3 ± 16.260.8 ± 18.5
Mental Health, Week 96, n = 0, 59NA ± NA72.3 ± 14.6
Reported Health Transition, Baseline, n = 105, 1233.1 ± 0.93.0 ± 0.9
Reported Health Transition, Week 24, n = 77, 903.5 ± 1.23.2 ± 1.2
Reported Health Transition, Week 48, n = 67, 773.2 ± 1.33.0 ± 1.3
Reported Health Transition, Week 72, n = 65, 691.6 ± 0.92.3 ± 1.1
Reported Health Transition, Week 96, n = 0, 61NA ± NA1.3 ± 0.7
SecondaryMean Fatigue Severity Scale Scores for Groups A and B Over Time (Part 1)

The Fatigue Severity Scale (FSS) is an instrument consisting of 10 self-administered questions. The FSS items were scored by calculating the average response to all answered items (including the 9 questions and the fatigue symptoms). Each of the 9 questions had answers within a score range of 1-7. A score of 1 for any question indicates less fatigue in everyday life and a score of 7 indicates a higher likelihood of fatigue in everyday life. The mean FSS scores are presented at Baseline (Day 1), Week 24, Week 48 and Week 72 (for Groups A and B) and at Week 96 (for Group B).

Time frame:
Baseline (Day 1), Week 24, Week 48 and Week 72, and Week 96
Reported as:
Mean · scores on a scale
Mean Fatigue Severity Scale Scores for Groups A and B Over Time (Part 1)
scores on a scalePEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)
Baseline, n = 104, 1143.6 ± 1.53.4 ± 1.7
Week 24, n = 69, 774.5 ± 1.74.7 ± 1.7
Week 48, n = 59, 634.7 ± 1.64.7 ± 1.5
Week 72, n = 58, 623.0 ± 1.54.3 ± 1.8
Week 96, n = 0, 57NA ± NA3.4 ± 1.5
SecondaryNumber of Participants With Fibrosis Grades 0 to 4 at Baseline (Part 1)

Liver fibrosis stage was scored using the METAVIR system (Grade 0 to 4). Grade 0 indicates no fibrosis, Grade 1 indicates stellate enlargement of portal tract but without septa formation, Grade 2 indicates enlargement of portal tract with rare septa formation, Grade 3 indicates numerous septa without cirrhosis and grade 4 indicates cirrhosis. The number of participants with fibrosis grades ranging from 0 to 4 at Baseline is presented.

Time frame:
Baseline (Day 1)
Reported as:
Number · Number of participants
Number of Participants With Fibrosis Grades 0 to 4 at Baseline (Part 1)
Number of participantsPEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1)PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1)
Grade 011158171
Grade 1384020571
Grade 2646823586
Grade 3181315103
Grade 4111611140
SecondaryNumber of Participants With Adverse Events and Serious Adverse Events (Part 1)

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.

Time frame:
Up to Week 96
Reported as:
Number · Number of participants
Number of Participants With Adverse Events and Serious Adverse Events (Part 1)
Number of participantsPEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1)PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1)
Number of participants with any AE1401497615310
Number of participants with any SAE22288142
SecondaryPercentage of Participants With Relapse Rates in Groups A1 and B1 at the End of Follow-up (Part 2)

Virological relapse rate was defined as percentage of participants with non-detectable HCV RNA (\< 15 IU/ml) at the EoT and detectable HCV RNA (≥ 15 IU/ml) at the end of FU. The end of treatment was defined as Week 48 in Group A1 and Week 72 in Group B1 and the end of follow-up was defined as Week 72 in Group A1 and Week 96 in Group B1.

Time frame:
Up to Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Relapse Rates in Groups A1 and B1 at the End of Follow-up (Part 2)
Percentage of participantsPEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2)
Percentage of Participants With Relapse Rates in Groups A1 and B1 at the End of Follow-up (Part 2)41.2 (18.4 to 67.1)38.5 (13.9 to 68.4)
SecondaryPercentage of Participants With Virological Response Rates in Group A1, B1, C and D at the End of the Treatment Period (Part 2)

ETR virological response rate at the end of treatment period was defined as the percentage of participants in each group with non-detectable HCV RNA at completion of the treatment period (HCV RNA quantitative PCR result \< 15 IU/ml at Week 24 for Group D, at Week 48 for Group A1, at Week 72 for Groups B1 and C). Participants without a HCV RNA PCR (missing values) at this time point were considered as non-responders in this calculation. The end of treatment period was defined as Week 48 for Group A1, Week 72 for Groups B1 and C1, and Week 24 for Group D.

Time frame:
Up to Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants With Virological Response Rates in Group A1, B1, C and D at the End of the Treatment Period (Part 2)
Percentage of participantsPEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2)
Percentage of Participants With Virological Response Rates in Group A1, B1, C and D at the End of the Treatment Period (Part 2)47.2 (30.4 to 64.5)52.0 (31.3 to 72.2)5.0 (0.1 to 24.9)90.5 (77.4 to 97.3)
SecondaryPercentage of Participants Achieving Sustained Virological Response in Groups C and D by Genotype at the End of Follow-up (Part 2)

The SVR was defined as the percentage of participants in each group with non-detectable HCV RNA result at 24 weeks post completion of the treatment period (HCV RNA \< 15 IU/ml at Week 48 of Group D and at Week 96 of Group C). Participants without a HCV RNA results at this time point were considered as non-responders. The end of follow-up was defined as Week 96 for Group C and Week 48 for Group D.

Time frame:
Up to Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Sustained Virological Response in Groups C and D by Genotype at the End of Follow-up (Part 2)
Percentage of participantsPEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2)
Percentage of Participants Achieving Sustained Virological Response in Groups C and D by Genotype at the End of Follow-up (Part 2)0.0 (0.0 to 16.8)73.8 (58.0 to 86.1)
SecondaryMean Short Form-36 Questionnaire Scores for Groups A1, B1, and C Over Time (Part 2)

The SF-36 is a quality of life instrument consisting of a 36-item questionnaire. The SF-36 items were scored and transformed according to the SF-36 Health Survey Manual \& Interpretation Guide. Summary scores for SF-36 dimensions (physical functioning, role functioning, bodily pain, general health, vitality, social functioning, mental health, health transition) as well as physical and mental summary measures were compiled after imputation of mean scores for missing items if more than 50% of dimension-related items were available. Scores for health transition ranged from 0 (worst) to 5 (best). Scores for all other dimensions ranged from 0 (worst) to 100 (best). The mean SF-36 scores were presented at Baseline (Day 1), Week 24, Week 48, Week 72 (for Groups A1, B1 and C) and at Week 96 (for Groups B1 and C). Lower score indicate worsening.

Time frame:
Baseline (Day 1), Week 24, Week 48, Week 72, and Week 96
Reported as:
Mean · scores on a scale
Mean Short Form-36 Questionnaire Scores for Groups A1, B1, and C Over Time (Part 2)
scores on a scalePEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2)
Physical functioning, Baseline, n = 22, 18, 1582.5 ± 22.583.1 ± 17.778.5 ± 28.8
Physical functioning, Week 24, n = 17, 13, 961.8 ± 25.851.2 ± 25.272.2 ± 24.9
Physical functioning, Week 48, n = 13, 8, 066.5 ± 22.876.3 ± 19.8NA ± NA
Physical functioning, Week 72, n = 10, 7, 177.0 ± 18.480.7 ± 9.345.0 ± NA
Physical functioning, Week 96, n = 0, 6, 0NA ± NA85.8 ± 17.7NA ± NA
Role Functioning- Physical, Baseline,n =22, 18, 1575.0 ± 33.662.0 ± 42.153.3 ± 41.0
Role Functioning - Physical, Week 24, n= 17, 13, 841.2 ± 44.115.4 ± 33.143.8 ± 43.8
Role Functioning - Physical, Week 48, n = 13, 8, 041.0 ± 41.356.3 ± 39.5NA ± NA
Role Functioning - Physical,, Week 72, n= 10, 7,160.0 ± 47.482.1 ± 37.40.0 ± 0.0
Role Functioning - Physical, Week 96, n = 0, 5, 0NA ± NA70.0 ± 32.6NA ± NA
Bodily Pain, Baseline, n = 21, 19, 1575.3 ± 26.776.3 ± 25.566.5 ± 31.7
Bodily Pain, Week 24, n = 17, 13, 857.9 ± 28.545.9 ± 27.954.9 ± 17.8
Bodily Pain, Week 48, n = 13, 8, 066.4 ± 31.654.6 ± 19.2NA ± NA
Bodily Pain, Week 72, n = 10, 7, 171.1 ± 30.170.4 ± 15.062.0 ± NA
Bodily Pain, Week 96, n = 0, 6, 0NA ± NA74.5 ± 19.3NA ± NA
General Health, Baseline, n = 22, 16, 1461.8 ± 18.856.7 ± 21.753.4 ± 19.1
General Health, Week 24, n = 17, 11, 852.8 ± 23.637.1 ± 14.157.1 ± 24.4
General Health, Week 48, n = 12, 8, 054.4 ± 21.056.3 ± 23.8NA ± NA
General Health, Week 72, n = 10, 7, 155.0 ± 21.859.9 ± 16.535.0 ± NA
General Health, Week 96, n = 0, 6, 0NA ± NA52.8 ± 18.8NA ± NA
Vitality, Baseline, n = 21, 18, 1554.0 ± 21.952.5 ± 19.345.0 ± 16.0
Vitality, Week 24, n = 17, 11, 837.8 ± 13.931.2 ± 21.743.1 ± 17.9
Vitality, Week 48, n = 13, 8, 043.2 ± 22.148.1 ± 17.3NA ± NA
Vitality, Week 72, n = 9, 7, 147.2 ± 23.160.2 ± 16.740.0 ± NA
Vitality, Week 96, n = 0, 6, 0NA ± NA56.9 ± 15.1NA ± NA
Social Functioning, Baseline, n = 22, 19, 1584.7 ± 18.578.9 ± 25.072.5 ± 33.5
Social Functioning, Week 24, n = 17, 13, 864.7 ± 26.656.7 ± 23.265.6 ± 23.9
Social Functioning, Week 48, n = 13, 8, 062.5 ± 27.578.1 ± 27.3NA ± NA
Social Functioning, Week 72, n = 10, 7, 177.5 ± 20.278.6 ± 15.725.0 ± NA
Social Functioning, Week 96, n = 0, 6, 0NA ± NA83.3 ± 17.1NA ± NA
Role Functioning -Emotional,Baseline,n =22, 18, 1571.2 ± 38.962.0 ± 42.753.3 ± 45.1
Role Functioning-Emotional, Week 24, n=17, 13, 843.1 ± 43.720.5 ± 37.445.8 ± 50.2
Role Functioning - Emotional, Week 48, n= 13, 8, 043.6 ± 39.454.2 ± 46.9NA ± NA
Role Functioning - Emotional, Week 72, n= 10, 7, 156.7 ± 49.881.0 ± 37.80.0 ± 0.0
Role Functioning - Emotional, Week 96, n = 0, 5, 0NA ± NA60.0 ± 43.5NA ± NA
Mental Health, Baseline, n = 21, 18, 1571.6 ± 18.162.9 ± 22.062.1 ± 20.8
Mental Health, Week 24, n = 17, 11, 858.8 ± 21.546.2 ± 18.662.0 ± 19.9
Mental Health, Week 48, n = 13, 8, 057.4 ± 24.061.0 ± 16.8NA ± NA
Mental Health, Week 72, n = 9, 7, 166.7 ± 24.066.9 ± 17.836.0 ± NA
Mental Health, Week 96, n = 0, 6, 0NA ± NA58.3 ± 15.1NA ± NA
Reported Health Transition,Baseline, n =22, 19, 153.0 ± 1.12.9 ± 0.93.3 ± 1.0
Reported Health Transition, Week 24, 17, 13, 93.8 ± 1.03.5 ± 1.23.2 ± 1.1
Reported Health Transition, Week 48, n = 13, 8, 02.9 ± 1.12.9 ± 1.1NA ± NA
Reported Health Transition, Week 72, n = 10, 7, 12.8 ± 1.22.6 ± 1.34.0 ± NA
Reported Health Transition, Week 96, n = 0, 6, 0NA ± NA2.0 ± 0.9NA ± NA
SecondaryMean Fatigue Severity Scale Scores for Groups A1, B1 and C Over Time (Part 2)

The FSS is an instrument consisting of 10 self-administered questions. The FSS items were scored by calculating the average response to all answered items (including the 9 questions and the fatigue symptoms). Each of the 9 questions had answers within a score range of 1-7. A score of 1 for any question indicates less fatigue in everyday life and a score of 7 indicates a higher likelihood of fatigue in everyday life. The mean FSS scores are presented at Baseline (Day 1), Week 24, Week 48 and Week 72 (for Groups A1, B1 and C) and at Week 96 (for Groups B1 and C).

Time frame:
Baseline (Day 1), Week 24, Week 48 and Week 72, and Week 96
Reported as:
Mean · scores on a scale
Mean Fatigue Severity Scale Scores for Groups A1, B1 and C Over Time (Part 2)
scores on a scalePEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2)
Baseline, n = 22, 17, 153.7 ± 1.63.8 ± 2.03.9 ± 1.9
Week 24, n = 17, 15, 94.2 ± 1.74.9 ± 1.64.8 ± 1.6
Week 48, n = 11, 7, 04.0 ± 1.54.5 ± 1.3NA ± NA
Week 72, n = 8, 7, 13.9 ± 1.93.8 ± 2.25.3 ± NA
Week 96, n = 0, 7, 0NA ± NA4.5 ± 1.9NA ± NA
SecondaryNumber of Participants With Fibrosis Grades 0 to 4 at Baseline (Part 2)

Liver fibrosis stage was based upon biopsy and scored using the METAVIR system (Grade 0 to 4). Grade 0 indicates no fibrosis, Grade 1 indicates stellate enlargement of portal tract but without septa formation, Grade 2 indicates enlargement of portal tract with rare septa formation, Grade 3 indicates numerous septa without cirrhosis and grade 4 indicates cirrhosis. The number of participants with fibrosis grades ranging from 0 to 4 at Baseline (Day 1) is presented.

Time frame:
Baseline (Day 1)
Reported as:
Number · Number of participants
Number of Participants With Fibrosis Grades 0 to 4 at Baseline (Part 2)
Number of participantsPEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2)
Grade 054143
Grade 163289
Grade 2446108
Grade 352511
Grade 454105
SecondaryNumber of Participants With Adverse Events and Serious Adverse Events (Part 2)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.

Time frame:
Up to Week 96
Reported as:
Number · Number of participants
Number of Participants With Adverse Events and Serious Adverse Events (Part 2)
Number of participantsPEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2)PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2)
Number of participants with any AE36251940437
Number of participants with any SAE132571

Adverse events

Collected over Up to Week 96. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)—22/142 (15.5%)139/142 (97.9%)
PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)—28/152 (18.4%)147/152 (96.7%)
PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1)—8/78 (10.3%)76/78 (97.4%)
PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1)—14/156 (9%)150/156 (96.2%)
PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1)—2/12 (16.7%)9/12 (75%)
PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2)—1/36 (2.8%)36/36 (100%)
PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2)—3/25 (12%)25/25 (100%)
PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2)—2/20 (10%)19/20 (95%)
PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2)—5/42 (11.9%)40/42 (95.2%)
PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2)—7/45 (15.6%)42/45 (93.3%)
PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2)—1/8 (12.5%)6/8 (75%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventPEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1)PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2)PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2)
PneumoniaInfections and infestations2/1421/1520/780/1560/120/360/250/200/420/451/8
Circulatory collapseVascular disorders0/1420/1520/780/1561/120/360/250/200/420/450/8
Ovarian CystReproductive system and breast disorders0/1420/1520/780/1561/120/360/250/200/420/450/8
Ovarian NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1420/1520/780/1561/120/360/250/200/420/450/8
Abdominal pain lowerGastrointestinal disorders0/1420/1520/780/1560/120/360/251/200/420/450/8
Jaundice CholestaticHepatobiliary disorders0/1420/1520/780/1560/120/360/251/200/420/450/8
AnaemiaBlood and lymphatic system disorders0/1422/1520/781/1560/120/360/250/200/422/450/8
PregnancyPregnancy, puerperium and perinatal conditions0/1420/1520/782/1560/120/360/250/201/422/450/8
CryoglobulinaemiaVascular disorders0/1420/1520/780/1560/120/361/250/200/420/450/8
Renal FailureRenal and urinary disorders0/1420/1520/780/1560/120/361/250/200/420/450/8
Most frequent other events
Showing 10 of 81
Most frequent other events
EventPEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1)PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2)PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2)
FatigueGeneral disorders86/14294/15235/7872/1564/1220/3614/2511/2021/4230/451/8
Influenza Like IllnessGeneral disorders60/14257/15241/7861/1565/1215/3614/257/2013/4214/451/8
HeadacheNervous system disorders42/14238/15210/7826/1561/128/363/255/208/4210/451/8
DepressionPsychiatric disorders30/14244/15220/7827/1560/127/361/251/205/427/451/8
PruritusSkin and subcutaneous tissue disorders36/14227/15219/7818/1562/126/365/253/208/4213/451/8
RashSkin and subcutaneous tissue disorders35/14239/15215/7824/1562/126/367/251/205/427/451/8
NauseaGastrointestinal disorders27/14222/15211/7815/1560/1210/363/252/207/427/451/8
Decreased AppetiteMetabolism and nutrition disorders16/14226/1526/7822/1560/1210/363/253/204/424/451/8
AlopeciaSkin and subcutaneous tissue disorders29/14239/1528/7827/1560/124/363/251/207/427/450/8
DyspnoeaRespiratory, thoracic and mediastinal disorders26/14225/15210/7813/1563/124/362/250/203/423/451/8

Baseline characteristics

Baseline characteristics are presented for the safety population which included all participants who received at least on dose of (either) study drug and had at least one post-baseline safety assessment.

Age, Continuous
Age, Continuous(years)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1)PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2)PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2)Total
Mean45.0 ± 10.744.2 ± 10.246.6 ± 9.040.5 ± 11.746.5 ± 9.544.6 ± 9.147.3 ± 9.846.6 ± 8.737.8 ± 11.141.1 ± 10.243.6 ± 15.443.5 ± 10.78
Sex: Female, Male
Sex: Female, Male(Participants)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1)PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2)PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2)PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2)PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2)Total
Female50532157488517203246
Male92995799828171525255470
08

Study locations

21 sites
  • Feldkirch, 6800, Austria
  • Gratwein, 8112, Austria
  • Graz, 8020, Austria
  • Graz, 8036, Austria
  • Innsbruck, 6020, Austria
  • Krems, 3500, Austria
  • Linz, 4010, Austria
  • Linz, 4020, Austria
  • Oberndorf, 5110, Austria
  • Oberpullendorf, 7350, Austria
  • Ried-innkreis, 4910, Austria
  • Salzburg, 5020, Austria
  • Villach, 9500, Austria
  • Wels, 4600, Austria
  • Wiener Neustadt, 2700, Austria
  • Wien, 1030, Austria
  • Wien, 1090, Austria
  • Wien, 1100, Austria
  • Wien, 1130, Austria
  • Wien, 1140, Austria
  • Wien, 1160, Austria
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2015
First posted
Dec 29, 2015
Start
May 2003
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Aug 4, 2016
Last update
Aug 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02641379
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 29, 2015
Start date
May 2003
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Aug 4, 2016
Last update
Aug 4, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin

Start the discussion